In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.